• 1
    Dougados M, Baeten D.Spondyloarthritis.Lancet2011;377:212737.
  • 2
    Van der Heijde D, Maksymowych WP.Spondyloarthritis: state of the art and future perspectives.Ann Rheum Dis2010;69:94954.
  • 3
    Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al.The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.Ann Rheum Dis2009;68:77783.
  • 4
    Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al.The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.Ann Rheum Dis2011;70:2531.
  • 5
    Van der Linden S, Valkenburg HA, Cats A.Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.Arthritis Rheum1984;27:3618.
  • 6
    Sieper J, van der Heijde D.Nonradiographic axial spondyloarthritis: new definition of an old disease? [review].Arthritis Rheum2013;65:54351.
  • 7
    Huerta-Sil G, Casasola-Vargas JC, Londono JD, Rivas-Ruiz R, Chavez J, Pacheco-Tena C, et al.Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up.Ann Rheum Dis2006;65:6426.
  • 8
    Sampaio-Barros PD, Bortoluzzo AB, Conde RA, Costallat LT, Samara AM, Bertolo MB.Undifferentiated spondyloarthritis: a longterm followup.J Rheumatol2010;37:11959.
  • 9
    Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al.The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort.Arthritis Rheum2009;60:71727.
  • 10
    Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al.Do patients with non-radiographic axial spondyloarthritis differ from patients with ankylosing spondylitis?Arthritis Care Res (Hoboken)2012;64:141522.
  • 11
    Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al.Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.Arthritis Rheum2008;58:198191.
  • 12
    Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, et al.Clinical and imaging efficacy of infliximab in HLA–B27–positive patients with magnetic resonance imaging– determined early sacroiliitis.Arthritis Rheum2009;60:94654.
  • 13
    Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, et al.Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial.Ann Rheum Dis2011;70:5906.
  • 14
    Song IH, Weiss A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, et al.Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.Ann Rheum Dis2013;72:8235.
  • 15
    Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al.Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).Ann Rheum Dis2013;72:81522.
  • 16
    Van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al.2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.Ann Rheum Dis2011;70:9058.
  • 17
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A.A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.J Rheumatol1994;21:228691.
  • 18
    Robinson PC, Wordsworth BP, Reveille JD, Brown MA.Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis.Ann Rheum Dis2013;72:1624.
  • 19
    Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al.The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis.Ann Rheum Dis2009;68 Suppl 2:ii144.
  • 20
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al.A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.J Rheumatol1994;21:22815.
  • 21
    McHorney CA, Ware JE Jr, Raczek AE.The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.Med Care1993;31:24763.
  • 22
    Haywood KL, Garratt AM, Dziedzic K, Dawes PT.Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness.Rheumatology (Oxford)2002;41:13807.
  • 23
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A.Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index.J Rheumatol1994;21:16948.
  • 24
    Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al.Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.Ann Rheum Dis2011;70:4753.
  • 25
    Landewe R, Rump B, van der Heijde D, van der Linden S.Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists.Ann Rheum Dis2004;63:5304.
  • 26
    Pham T, Landewe R, van der Linden S, Dougados M, Sieper J, Braun J, et al.An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.Ann Rheum Dis2006;65:16205.
  • 27
    Vander Cruyssen B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J, et al.The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.Ann Rheum Dis2007;66:10727.
  • 28
    Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P.Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.Arthritis Care Res (Hoboken)2010;62:13629.
  • 29
    Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, et al.Baseline predictors of response and discontinuation of tumor necrosis factor-α blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.Arthritis Res Ther2011;13:R94.
  • 30
    Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.Ann Rheum Dis2008;67:127681.
  • 31
    Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL.Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.Rheumatology (Oxford)2010;49:56370.
  • 32
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al.Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.Ann Rheum Dis2004;63:1594600.
  • 33
    Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al.Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).Arthritis Rheum2005;52:58291.
  • 34
    Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al.Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.Arthritis Rheum2006;54:213646.
  • 35
    Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, et al.Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.Arthritis Rheum2008;58:340212.
  • 36
    Bakland G, Alsing R, Singh K, Nossent JC.Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27.Arthritis Care Res (Hoboken)2013;65:44853.
  • 37
    Tournadre A, Pereira B, Lhoste A, Dubost J, Ristori J, Claudepierre P, et al.Differences between women and men with recent onset axial spondyloarthritis: Results from the DESIR cohort.Arthritis Care Res (Hoboken)2013. E-pub ahead of print.
  • 38
    Baeten D, Breban M, Lories R, Schett G, Sieper J.Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?Arthritis Rheum2013;65:1220.
  • 39
    Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al.Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis.Ann Rheum Dis2011;70:136974.
  • 40
    Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al.The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study.Ann Rheum Dis2012;71:120711.
  • 41
    Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kaufmann C, Rodevand E, et al.Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.Rheumatology (Oxford)2012;51:147983.